Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)

NCT00820755 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

583

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Cetuximab plus Platinum-based Doublet Chemotherapy
DRUG: Cetuximab 500 mg/m^2
DRUG: Cetuximab 250 mg/m^2

Sponsor

Merck KGaA, Darmstadt, Germany